Anti-AIDS Flashcards Preview

Class: Immuno Block > Anti-AIDS > Flashcards

Flashcards in Anti-AIDS Deck (54)
Loading flashcards...
1

Overall HIV pathogenesis

RESTING CD4+ lymphocytes that have an avg lifespan of YEARS carrying HIV infection that outcompete
Recently infected CD4+ lymphocytes (avg lifespan of 2.2days)

2

4 Classes of Anti-viral Drugs

1) Drugs that BLOCK HIV ENTRY into host CD4+ Tcells [FUSION INHIBITORS] - Not first-line drugs anymore, rather SECOND-LINE
2) Drugs that BLOCK Reverse Transcriptase
3) Drugs that BLOCK Integration into host genome via INTEGRASE
4) Drugs that BLOCK Proteolytic activity to make functional, cleaved subunits via PROTEASE

3

Mechanism of Viral entry

1) Gp120 protein (VIRAL SURFACE) recognized by CD4 + Coreceptors (CCR5 or CXCR4) -> Gp120 gets stripped off
* Gp41 is bound/protected by Gp120 - Does not uncoil unless needed
2) Gp120 Removed -> Gp41 UNCOILS -> Sticks end into nearby CD4 cells
3) Gp41 RECOILS - Refolding of Gp41 [re-associates N/C termini] -> Reels in CD4
4) Membrane fusion

4

DRUG CLASS 1: Fusion Inhibitor
What is its mechanism?

Synthetic Amino Acid that mimics C-terminus of GP41 -> Prevents refolding/recoiling of Gp41 -> CD4 does NOT get reeled in

5

Name the FUSION INHIBITOR anti-AIDS drugs (2)

1) Enfuvirtide - gp41 targeting
2) Maraviroc - Hu CCR5 targeting

6

Why did ENFUVIRTIDE become a 2nd-line Anti-AIDS drug?

1) PHARMACODYNAMICS: High first pass metabolism and thus requires 2 subcutaneous injections/day
2) SIDE EFFECT: Skin reaction at the site of injection + Greater pneumonia incidence
3) RESISTANCE: Mutation appearance at the N-terminus of gp41 (binding site of enfuvirtide)

7

What is the specific mechanism of ENFUVIRTIDE?

SYNTHETIC C-peptide sequence that competitively binds to N-terminal region -> Prevents N/C termini re-association [recoiling] of gp41 -> Prevents FUSION of virus and CD4+

8

What is the specific mechanism of MARAVIROC?

Targets HUMAN CCR5 Co-receptor of CD4+ Tcells -> gp120 can not recognize -> Blocks HIV entry

9

What is the basis of a drug targeting a human receptor? (Maraviroc)

Targeting human components: Masks the human receptor so that the HIV virus can never find it

10

Caveat of Maraviroc Usage

Only works for CCR5-TROPIC HIV ISOLATES
[Diagnostic test: determine by PCR]
If the HIV isolates utilize CCR5 and NOT CXCR4 as the co-receptor

* If HIV isolate mutates to NON-CCR5 tropic, maraviroc is NO LONGER effective, especially in LATE stages *

11

How is MARAVIROC metabolized? What does this implicate?

Metabolized by p450 enzymes -> p450 inducers and inhibitors can influence maraviroc levels by increasing or decreasing its half life

* Take caution if pt is taking any other drugs that utilize p450 enzymes for metabolism *

12

What is the mechanism of resistance developing to MARAVIROC?

Mutant HIV strains that use CXCR4 (not CCR5) to gain entry into CD4+ T cell

13

DRUG CLASS 2: Name the reverse transcriptase inhibitors (4).

NON-NUCLEOSIDE
1) Efavirenz
2) Etravirine

NUCLEOSIDE:
1) Emitricitabine
2) Tenofovir

14

Activities of HIV Reverse Transcriptase (2)

ACTIVITY 1: SYNTHETASE [p66 Reverse Transcriptase] -
Uses tRNA (Lys) to serve as 3'OH primer -> Synthesizes DNA Strand
ACTIVITY 2: RNA-ase [RNAseH] -
Chews up RNA template strand but leaves a little bit of RNA to serve as PRIMER for second DNA strand synthesis

RESULT: dsDNA HIV DNA genome is created and can now become integrated into host

15

Measurements of HIV progression

1) CD4+ Count (monitors pt's immune system status + susceptibility to opportunistic infn of virus)
2) HIV-1 RNA levels (most effective at monitoring therapeutic intervention) - RNA levels drop 10-100x within 1wk of treatment (protease, RT inhibitor)

16

What are the 2 nucleoside reverse transcriptase inhibitors?

Emtricitabine
Tenofovir

17

What is the specific mechanism of the nucleoside reverse transcriptase?

Emtricitabine + Tenofovir are nucleoside analogs that bind active site of HIV RT - do NOT have 3'OH -> Immediately terminates chain elongation

SUICIDE SUBSTRATES: 3'OH of growing DNA strand attacks alpha phosphate of drug -> No subsequent 3'OH -> CHAIN STOPS HERE

18

What does it mean that EMTRICITABINE + TENOFOVIR are "pro-drugs"?

They are NUCLEOSIDES = no phosphates (bulky negative charge that would impede entry into cells)

Nucleoside or NMP [Pro-drug] -> Facilitate entry -> Pt's kinases phosphorylate drug [Drug] -> Act as nucleoside reverse transcriptases

19

What confers selectivity of EMTRICITABINE + TENOFOVIR for HIV RT rather than human DNA polymerase?

HIV RT is a "sloppier enzyme" - Can bind WELL to the nucleoside drug
Human nuclear DNA polymerases - Does NOT bind well to the drug

20

How is the half life of EMTRICITABINE + TENOFOVIR extended?

Phosphorylation by pt's enzymes -> Active drug form [negatively charged] is now trapped inside the cell

21

What is the most common adverse side effect of EMTRACITABINE + TENOFOVIR? What is the mechanism of this side effect?

Muscle soreness/weakness [LACTIC ACIDOSIS] -

Generally, NRTIs are selective for HIV RTs EXCEPT for MITOCHONDRIAL POLYMERASES -> Lactic acidosis

22

What is the mechanism of resistance of EMTRICITABINE + TENOFOVIR?

Mutation in the active site of HIV RT
Each NRTI has UNIQUE profile of resistance mutations

23

Classify the chemical composition of EMTRICITABINE.

Fluorinated analog of lamivudine (one of the first NRTIs)
*Fluorination - decreases its degradation -> increases its half life

24

Classify the chemical composition of TENOFOVIR.

Adenosine + Phosphate (AMP analog)

* Technically NUCLEOTIDE reverse transcriptase inhibitor *

25

Mechanism of TENOFOVIR entry from its inactive prodrug form to active form inside cells.

Drug AMP analog (pro-drug form) gets into intestinal lumen -> Protective groups are removed -> Enters cells via ENDOCYTOSIS -> Pt's kinases phosphorylate to triphophosphate

26

Selective advantage of TENOFOVIR's monophosphate moiety, compared to other NRTIs

Phosphate group does limit its entry into cells BUT it also OVERCOMES rate limiting phosphorylation step in CD4+ T cells

Overcoming rate-limiting phosphorylation step >> Cost of limited drug entry into cells

27

Combo Pill: EMTRICITABINE + TENOFOVIR

TRUVADA

28

Other advantages of TENOFOVIR:

1) Interacts little with P450 -> Little side effects
2) Develops very little resistance slowly: TENOFOVIR retains activity even if there is resistance to other NRTIs

29

What are the 2 non-NRTIs?

Efavirenz
Etravirine

30

Mechanism of EFAVIRENZ + ETRAVIRINE:

non-NRTIs = ALLOSTERIC RT inhibitors
Mechanism: Bind to site adjacent to RT active site -> Induces conformational change that blocks RT activity